PROFIL PRESEPAN OBAT PADA PASIEN PEMBESARAN PROSTAT JINAK ATAU BPH (BENIGN PROSTATIC HYPERPLASIA) TAMSULOSIN DAN DUTASTERIDE DI INSTALASI RAWAT JALAN RUMAH SAKIT “X” CIPUTAT PERIODE OKTOBER-DESEMBER 2024
Abstract
Benign prostatic hyperplasia (BPH) is a term used in histopathology to describe the presence of enlarged stromal and epithelial cells in the prostate gland. In essence, BPH mostly affects elderly men whose testes are still capable of making testosterone. According to earlier research, using dutasteride and tamsulosin together may have greater therapeutic results for BPH and significantly lower the chance that symptoms may worsen. Purpose: The objective of this study was to identify salient features of Tamsulosin and Dutasteride prescriptions for benign prostatic enlargement (BPH) at Ciputat "X" Hospital's outpatient clinic from October to December 2024.. Methods: This research method is descriptive, the data is taken restropectively, namely research that looks back, meaning data collection from medical records of outpatients with BPH diagnoses. Results: This study showed that, 101 samples of BPH patients were obtained, the most BPH patients occurred at the age of 56-65 (47.5%), the most work status was self-employed (44.6%), the mosttypes oftherapy were combination therapy oftamsulosin with dutasteride (56.4%), α1-blocker drug classes that got a percentage (100%), the most length of therapy was 1 month (98.0%), and other groups of drugs prescribed Antibiotics (37.5%).
Keywords
References
Alysa, A. R., Langitan, A., & Wahyuni, R. D. (2019). Benign prostatic hyperplasia
(BPH). Jurnal Medical Profession (MedPro), 1(2), 467–473.
https://doi.org/10.1016/B978-0-12-801238-3.64812-2
Arsi, R., Afdhal, F., & Fatrida, D. (2022). Faktor-Faktor Yang Berhubungan
Dengan Kejadian Benigna Prostat Hiperplasia Di Poli Klinik Rsud Bayung
Lencir Tahun 2021. Indonesian Journal of Helath and Medical, 2(1), 33– 44.
http://ijohm.rcipublisher.org/index.php/ijohm
Ayu, D., Alit, K., Dwie, I.M., Susila, P., Nara, A.A.N., Badung, M.K., 2021.
Hubungan Lower Urinary Tract Symptoms ( Luts ) Terhadap Kualitas Hidup
Pasien BPH Di Klinik Urologi Rsd Mangusada Badung.
Bachtiar, S. M. (2019). Pengaruh Pmr (Progressive Muscle Relaxation) Terhadap
Penurunan Intensitas Nyeri Pada Pasien Post Op Bph (Benign Prostate
Hiperplasia). Media Keperawatan: Politeknik Kesehatan Makassar, 10(2), 92.
https://doi.org/10.32382/jmk.v10i2.1320 Sutanto, R. L. (2021). Hiperplasia
prostat jinak: manajemen tatalaksana dan pencegahan. JIMKI: Jurnal Ilmiah
Mahasiswa Kedokteran Indonesia, 8(3), 90–97.
https://doi.org/10.53366/jimki.v8i3.230
Bortnick E, Brown C, Simma-Chiang V, Kaplan SA. Modern best practice in the
management of benign prostatic hyperplasia in the elderly. Vol. 12,
Therapeutic Advances in Urology. SAGE Publications Inc.; 2020
Devika VS, Krishna MJ, Sakkeena A, Sajeev AR, Kumar ES, Prasobh GR. 2020,
A pilot study to evaluate improvement in lower urinary tract symptoms with
tamsulosin and dutasteride combination therapy in patients with beningn
prostatic hyperplasia and to evaluate the impact of patient counselling on
quality of life of patents. World Journal of Pharmaceutical Research, 9(1) :
-844.
Devlin CM, Simms MS, Maitland NJ. Benign prostatic hyperplasia – what do we
know? Vol. 127, BJU International. John Wiley and Sons Inc; 2021. p. 389–
Ginanjar, M. T., Permane, S. Y., & Nur, K. Z. (2022). Asuhan Keperawatan Nyeri
Akut pada Tn. K Pasien Post Operasi TURP dengan Benigna Prostat
Hyperplasia di Rumah Sakit Wijaya Kusuma Purwokerto. Jurnal Pengabdian
Mandiri, 1(6), 913–918. http://bajangjournal.com/index.php/JPM
Gravas S, Cornu JN, Gacci M, Gratzke C, Herrmann TRW, Mamoulakis C, et al.
Management of non-neurogenic male lower urinary tract symptoms (LUTS), incl. Benign Prostatic Obstruction (BPO): EAU guideline. European
Association of Urology Guidelines :1-77
Kementrian Kesehatan RI. (2019). Profil kesehatan Indonesia 2018 (indonesia
Health Profile 2018). Diakses dari
http://www.depkes.go.id/resources/download/pusatin/profilkesehatan
indonesia/Data-dan-Informasiprofil-Kesehatan-Indonesia-2018.pdf
Joo, K.J., Sung, W.S., Park, S.H., Yang, W.J., Kim, T.H., 2014. Comparison of α-
blocker monotherapy and α-blocker plus 5α-reductase inhibitor combination
therapy based on prostate volume for treatment of benign prostatic hyperplasia.
Journal of International Medical Research 40, 899–908.
https://doi.org/10.1177/14732300120 4000308
Launer BM, McVary KT, Ricke WA, Lloyd GL. The rising worldwide impact of
benign prostatic hyperplasia. BJU Int. 2021 Jun 1;127(6):722–8.
Lokeshwar SD, Harper BT, Webb E, Jordan A, Dykes TA, Neal DE, et al. 2019.
Epidemiology and treatment modalities for the management of benign prostatic
hyperplasia. Translational andrology and urology. 8(5): 529–539.
Maulana, D. A. (2021). Faktor Yang Mempengaruhi Kejadian Batu Saluran Kemih
Pada Pasien Benign Prostate Hyperplasia. Jurnal Penelitian Perawat
Profesional,3(3),603–610. http://jurnal.globalhealthsciencegroup.com/index.php/JPPP/article/view/557
Nurdianto H, Alif S, Djojodimedjo T. Comparative Efficacy of Intermittent and
Daily Doxazosin Therapy For LUTS Associated With BPH. JURI.
;18(1):6-12.
Purnomo, B. B. (2016). Dasar-dasar urologi (3th ed). Jakarta: Sagung Seto.
Shum CF, Lau W, Teo C. 2017. Medical therapy for clinical benign prostatic
hyperplasia: α1 antagonists, 5α reductase inhibitors and their combination.
Asian journal of urology. 4(3): 185–190.
Suryawan, B., 2016. Hubungan Usia Dan Kebiasaan Merokok Terhadap Terjadinya
BPH. Jurnal Medika Malahayati 3, 102–107.
Sutanto, R. (2021). Benign prostatic hyperplasia. JIMKI: Jurnal Ilmiah Mahasiswa
Kedokteran Indonesia, 8(3), 90-97. https://doi.org/10.53366/jimki.v8i3.230.
Tjahjodjati, M.soebandi, D., Umbas, R., Mochtar, C. A., Daryanto, B., Noegroho,
bambang s., Daryanto, H. r., Warli, syah mirsa, Hakim, L., & Syahrir, S.
(2021). Panduan Praktik Klinis Pembesaran Prostat Jinak (Benign Prostatic
Hyperplasia/BPH).
DOI: http://dx.doi.org/10.52031/phrase.v5i1.1003
Refbacks
- There are currently no refbacks.